Leerink Partners analyst Roanna Ruiz has reiterated their bullish stance on SCPH stock, giving a Buy rating on August 8.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roanna Ruiz’s rating is based on scPharmaceuticals’ impressive financial performance and strategic advancements. The company reported a significant year-over-year revenue growth of 99% in the second quarter of 2025, driven primarily by its cardiology sector, with promising early results in nephrology. The rapid adoption by nephrologists and the expansion to approximately 4,700 unique prescribers indicate a strong market presence.
Additionally, scPharmaceuticals is benefiting from favorable Medicare Part D dynamics, which are improving patient access and prescription fill rates. The company’s IDN business is also showing robust growth, contributing substantially to total sales. Furthermore, the upcoming sNDA submission for the autoinjector program is expected to enhance market penetration by significantly reducing costs and treatment times. These factors, combined with a solid cash position and strategic focus on profitability, underpin the Buy rating.
In another report released on August 8, Craig-Hallum also reiterated a Buy rating on the stock with a $12.00 price target.